Autologous Haematopoietic Stem Cell Transplantation (HSCT) for the regeneration of insulin-producing pancreatic cells in type 1 diabetics
Mundy L, Hiller JE
Record ID 32010001659
English
Authors' recommendations:
This small case-series demonstrated that autologous stem cell transplantation is a viable technique for the remission of Type 1 diabetes in the majority of patients, however it remains to be seen whether or not the benefits outweigh the risks, including those of drug toxicity. A randomised controlled trial should be conducted that includes a group of patients who receive no intervention or only immunosuppression or immunomodulation. In addition, long-term follow-up data for all patients needs to be reported. It would be prudent to await the results of the randomised controlled trials summarised in the comparator section.As many patients who undergo immunosuppression treatment with cyclosporine experience remission to disease, the results from this study may be heavily confounded. Therefore that no further review by HealthPACT is currently required as routine scanning will identify any relevant studies published in the future.
Details
Project Status:
Completed
Year Published:
2010
URL for published report:
Not Available
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Australia
MeSH Terms
- Diabetes Mellitus, Type 1
- Insulin-Secreting Cells
- Pancreas
- Transplantation, Autologous
Contact
Organisation Name:
Adelaide Health Technology Assessment
Contact Address:
School of Public Health, Mail Drop 545, University of Adelaide, Adelaide SA 5005, AUSTRALIA, Tel: +61 8 8313 4617
Contact Name:
ahta@adelaide.edu.au
Contact Email:
ahta@adelaide.edu.au
Copyright:
Adelaide Health Technology Assessment (AHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.